SCHEMBL1688142

SCHEMBL1688142

Cc1cccc(C)c1N1CCCC(CO)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KHK P50053 1/20 0.50
▸ EPHX2 P34913 2/20 0.48
▸ PDE10A Q9Y233 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ RAB9A P51151 2/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTGER4 P35408 2/20 0.42
▸ MAP4K4 O95819 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ IRAK1 P51617 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ TYMP P19971 2/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ MTOR P42345 1/20 0.40
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1688137 0.90 SLC6A2 (0.44) KHKEPHX2PDE10APTGER4SMN1; SMN2
SCHEMBL15160355 0.83 MAP4K4 (0.44) KHKPDE10AMAP4K4HTTKMT2A
SCHEMBL15158612 0.79 C5AR1 (0.38) KHKPDE10AMAP4K4HTTKMT2A
SCHEMBL7790528 0.76 EPHX2 (0.51) KHKEPHX2CYP2D6RAB9APTPN1
SCHEMBL6648521 0.76 CYP2D6 (0.52) EPHX2CYP2D6RAB9APTPN1MAP4K4
SCHEMBL21135739 0.76 CYP2D6 (0.52) EPHX2CYP2D6RAB9APTPN1MAP4K4
SCHEMBL21135447 0.76 CYP2D6 (0.52) EPHX2CYP2D6RAB9APTPN1MAP4K4
SCHEMBL15160352 0.73 SLC6A2 (0.43) PDE10ASMN1; SMN2POLBHTTALDH1A1
SCHEMBL12578065 0.72 SRC (0.41) KMT2AALDH1A1
SCHEMBL15462283 0.71 ALDH1A1 (0.61) SMN1; SMN2POLBHTTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2703393-A1 CYCLIC AMIDE DERIVATIVE Mochida Pharmaceutical Co., Ltd. (JP) 2014-03-05 — — EP disclosed
WO-2012046869-A1 CYCLIC AMIDE DERIVATIVE 持田製薬株式会社 (JP) 2012-04-12 — — WO disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 — — US disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 — — US disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 — — US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 — — US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 — — US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 — — US disclosed
EP-2011788-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2009-01-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186909-A1 Oxadiazolidinedione Compound GPR119, GPR39, GPR65 KHK 886/4885EPHX2 4216/4885PDE10A 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback